The summary for the Molecular Therapy Core Centers Federal Grant is detailed below.
It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section.
If these sections are incomplete, please visit the website of the government agency that is offering this grant.
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Individuals For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Information not provided
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for Core Center Grants to support molecular therapy research to develop treatments for cystic fibrosis and other genetic diseases of interest to NIDDK. Core Centers will provide shared resources to enhance the efficiency of research and foster collaborations within and among institutions with strong existing base of research relevant to gene transfer and gene correction technologies. Centers will also support a Pilot and Feasibility Program and an Educational Enrichment Program. This program is intended to foster research toward the goal of developing molecular therapies for the treatment of cystic fibrosis. Therefore, applicants should propose a central focus on molecular therapy for cystic fibrosis. Centers should also have a focus on development of new approaches for gene transfer and achieving gene correction. Many common principles are involved in the development of safe methods for targeting and achieving long- term expression of therapeutic genes for most genetic disease. Therefore, Core Center resources may also be made available to scientists developing gene therapy and gene correction approaches for genetic endocrine, metabolic, digestive, liver, kidney, urologic, and hematologic diseases.